ストックスクリーナーアプリを入手
1.6607
1.73%
-0.0293
アフターアワーズ：
1.66
-0.0007
-0.04%
前日終値:
$1.69
開ける：
$1.62
24時間の取引高:
6,263
Relative Volume:
0.23
時価総額：
$66.93M
収益：
$1.88M
当期純損益:
$-15.57M
株価収益率:
-1.9538
EPS:
-0.85
ネットキャッシュフロー:
$-50.09M
1週間 パフォーマンス:
+7.14%
1か月 パフォーマンス:
-10.23%
6か月 パフォーマンス:
-31.94%
1年 パフォーマンス:
+82.70%
1日の値動き範囲:
$1.62
$1.71
1週間の範囲:
$1.50
$1.75
52週間の値動き範囲:
$0.7777
$4.00
Beyondspring Inc Stock (BYSI) Company Profile
BYSI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BYSI
Beyondspring Inc
|
1.6607 | 66.93M | 1.88M | -15.57M | -50.09M | -0.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.65 | 105.75B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.68 | 78.76B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
632.04 | 37.79B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.50 | 31.28B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.77 | 27.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-12-02 | ダウングレード | BofA Securities | Buy → Underperform |
| 2021-12-02 | ダウングレード | Jefferies | Buy → Hold |
| 2021-12-01 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-12-01 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-09-09 | 開始されました | Robert W. Baird | Outperform |
| 2021-08-04 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-04-05 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-01-11 | 開始されました | BofA Securities | Buy |
| 2020-12-29 | 開始されました | Evercore ISI | Outperform |
| 2020-02-07 | 開始されました | Jefferies | Buy |
| 2020-01-10 | 開始されました | Nomura | Buy |
| 2019-12-03 | 開始されました | William Blair | Outperform |
| 2019-07-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-04-30 | ダウングレード | Maxim Group | Buy → Hold |
| 2018-10-25 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Beyondspring Inc (BYSI) 最新ニュース
BeyondSpring (BYSI) Stock Drops Amidst Biotech Sector Volatility - GuruFocus.com
Germ Cell Tumors Market to Register Significant Growth at a CAGR of 5.5% by 2034 | DelveInsight - PR Newswire UK
CTLA-4 Inhibitors Market to Advance at Moderate CAGR During the Study Period (2020-2034) | DelveInsight - PR Newswire UK
Retail investors reap multibagger gains by betting on these 29 - Oficjalny Portal Gminy Brzesko
BeyondSpring (NASDAQ:BYSI) Shares Up 4.5%Here's Why - MarketBeat
BeyondSpring (NASDAQ:BYSI) Trading 4.5% Higher – Here’s Why - Defense World
Non-small Cell Lung Cancer Treatment Market 2032: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - The Globe and Mail
Non-small Cell Lung Cancer Treatment Market 2032: Clinical - openPR
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
BeyondSpring Presents Updated Efficacy Results from a Phase - GlobeNewswire
BeyondSpring's Lung Cancer Drug Shows 89% Disease Control Rate in Phase 2 Trial | BYSI Stock News - StockTitan
ROS1 Inhibitors Market Booms as Demand for Targeted Cancer Therapies Escalates | DelveInsight - The Malaysian Reserve
BeyondSpring (BYSI) Stock Drops Amid Biotech Sector Volatility - GuruFocus.com
Neutropenia Treatment Market to hit USD 20.8 billion by 2032, says Global Market Insights Inc. - GlobeNewswire
BioWorld Cancer Index continues to decline amid broader market gains - BioWorld Online
Biotech Stocks Facing FDA Decision In November - RTTNews
BYSI (BeyondSpring) Cash From Discontinued Investing Activi - GuruFocus.com
Marshall Wace LLP Buys Shares of 10,538 Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
Renaissance Technologies LLC Increases Stock Holdings in Mesa Air Group, Inc. (NASDAQ:MESA) - Defense World
CDK4/6 Inhibitors Market to Grow at Healthy Growth Rate by 2034 Owing to Expanded Usage of Approved Blockbuster CDK4/6 Inhibitors in Early-stage Breast Cancer and the Emergence of Newer Players in Other Indications | DelveInsight - PR Newswire UK
Caspase 8 Market Analysis, Trends, Growth, Research And Forecast 2030 - La Funcion mx
G-CSF (Granulocyte Colony Stimulating Factors) Market Size, Analysis, Trends, Overview And Forecast To 2033 - WhaTech
BYSI Sees Quick 5.39% Surge Amid Low Trading Volume - GuruFocus.com
BYSI: BeyondSpring Inc. Stock Surges 7.27% Amid Market Fluctuati - GuruFocus.com
BeyondSpring (BYSI) Stock Surges 6.83% Amid High Volume Trading - GuruFocus.com
Acadian Asset Management LLC Has $34,000 Stock Position in BeyondSpring Inc. (NASDAQ:BYSI) - Defense World
Chemotherapy Induced Neutropenia Market Size is Set for Rapid - openPR
BeyondSpring reports promising phase 2 NSCLC study results - Investing.com
BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC - MSN
BeyondSpring reports safer NSCLC therapy option - Investing.com India
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 - StockTitan
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 - StockTitan
BeyondSpring presented interim Phase 2 data on 303 Study - TipRanks
BeyondSpring Presents Efficacy/Safety Results from a Phase - GlobeNewswire
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase - GlobeNewswire
BeyondSpring (NASDAQ:BYSI) Trading Up 3.3% - MarketBeat
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type... - Markets Insider
BeyondSpring announces Dublin-3 final phase 3 efficacy data - TipRanks
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respira - GlobeNewswire
BeyondSpring Announces Oral Presentation at the 2024 World - GlobeNewswire
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin - StockTitan
Is BeyondSpring (NASDAQ:BYSI) In A Good Position To Invest In Growth? - Yahoo Finance
BeyondSpring Inc. Reports Mid-Year Financials - TipRanks
Global Chemotherapy Drugs Market to Grow Substantially at a CAGR of ~9% by 2030 | DelveInsight - The Malaysian Reserve
BeyondSpring (NASDAQ:BYSI) Stock Price Down 0.5% - MarketBeat
BYSI (BeyondSpring) EV-to-Revenue : 40.75 (As of Aug. 19, 2024) - GuruFocus.com
BYSI (BeyondSpring) GF Value Rank : 10 (As of Aug. 18, 2024) - GuruFocus.com
BYSI (BeyondSpring) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2023) - GuruFocus.com
Asia Deal Watch: Ocumension Obtains Chinese Rights To Eight Alcon Products - Scrip
BioWorld Cancer Index drops overall; Blueprint, TG catapulted in Q1 - BioWorld Online
Beyondspring Inc (BYSI) 財務データ
収益
当期純利益
現金流量
EPS
0.50%
1.47%
大文字化:
|
ボリューム (24 時間):